Literature DB >> 3485110

Determination of tenoxicam in human plasma by high-performance liquid chromatography.

P Heizmann, J Körner, K Zinapold.   

Abstract

A high-performance liquid chromatographic method for the determination of tenoxicam in plasma has been developed. Tenoxicam was extracted from buffered plasma (pH 3 or 4, respectively) with dichloromethane and the evaporated extracts were analysed on a C18 reversed-phase column using a methanol-phosphate buffer mobile phase and with UV detection at 371 nm. The detection limit was 20 ng/ml using a 0.5-ml sample. The method is selective with respect to the 5'-hydroxy metabolite, which is present in plasma after multiple administration of tenoxicam; this metabolite may also be determined using this procedure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485110     DOI: 10.1016/s0378-4347(00)83256-9

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Plasma tenoxicam concentrations after single and multiple oral doses.

Authors:  C Crevoisier; P Heizmann; I Forgo; U C Dubach
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

2.  Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.

Authors:  D Hartmann; A Korn; M Komjati; G Heinz; P Haefelfinger; R Defoin; W K Waldhäusl
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

3.  Intraocular and plasma kinetics of tenoxicam in rabbits.

Authors:  M Del Puppo; M G Kienle; R Ratiglia; D Galimberti; G Acerbi; L Boerci; L Marabini; E Chiesara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

4.  Single and multiple dose pharmacokinetics of tenoxicam in the elderly.

Authors:  O G Nilsen; R A Walstad; M Eckert; P Heizmann; A Bückert; T Am; I Løge; J Unnvik; E Thue
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  The influence of cholestyramine on the elimination of tenoxicam and piroxicam.

Authors:  T W Guentert; R Defoin; H Mosberg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.

Authors:  M S al-Ghamdi; F A al-Mohanna; Z H al-Mustafa; I S al-Saeed
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Tenoxicam concentrations in synovium and joint cartilage in humans.

Authors:  B Bannwarth; P Netter; F Lapicque; D Mainard; P Fener; P Gillet; A Gaucher
Journal:  Agents Actions       Date:  1991-03

Review 8.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.